1. Enders G. Paramyxovirüses. In: Baron S, editor. Medical Microbiology, 4th Edition. The University of Texas Medical Branch at Galveston.; 1996.
2. Park GYS, Tishkowski K. Paramyxovirüs. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
3. Rima B, Balkema-Buschmann A, Dundon WG, et al. ICTV Virüs Taxonomy Profile: Paramyxoviridae. J Gen Virol 2019;100(12):1593–4.
4. Rima B, Collins P, Easton A, et al. ICTV Virüs Taxonomy Profile: Pneumoviridae. J Gen Virol 2017;98(12):2912-13.
5. ssRNA(-)ViralZone. https://viralzone.expasy.org/237.
6. Paramyxovirüses In: Murray P R, Rosenthal K S, Pfaller M A, eds. Medical Microbiology, 7th Edition, Elsevier Saunders Philadelphia; 2013:512.
7. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and Clinical Impact of Parainfluenza Virüs Infections in Otherwise Healthy Infants and Young Children < 5 Years Old.
J Infect Dis 1997;175(4):807–13.
8. Rima B, Balkema-Buschmann A, Dundon WG, et al. ICTV Virüs Taxonomy Profile: Paramyxoviridae. J Gen Virol 2019;100(12):1593–4.
9. Fry AM, Curns AT, Harbour K, Hutwagner L, Holman RC, Anderson LJ. Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin Infect Dis 2006;43(8):1016–
22.
10. Elboukari H, Ashraf M. Parainfluenza Virüs. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
11. Russell E, Ison MG. Parainfluenza Virüs in the Hospitalized Adult. Clin Infect Dis 2017;65(9):1570–6.
12. Ruth A.Karron PLC. Parainfluenza Virüses. In: Knipe DM, Howley PM, eds. Fields Virology, 6th edition. Wolter Kluwer/Lippincott Williams and Wilkins; 2013: 996-1023.
13. Branche AR, Falsey AR. Parainfluenza Virüs Infection. Semin Respir Crit Care Med 2016;37(4):538–54.
14. Seo S, Xie H, Leisenring WM, Kuypers JM, Sahoo FT, Goyal S, et al. Risk Factors for Parainfluenza Virüs Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation. Biol Blood
Marrow Transplant 2019;25(1):163-171.
15. Ison MG. Parainfluenza Virüses. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition. Elsevier Saunders Phila-
delphia; 2015: 1937-41.
KABAKULAK VİRÜSÜ
KAYNAKLAR
1. Noor A, Krilov LR. Mumps. Pediatr Rev 2023;44(11):662–4.
2. Litman N, Baum SG. Mumps Virüs. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition. Elsevier Saunders
Philadelphia; 2015: 1942-1947.
3. Tolpin MD. Mumps virüs. In: Belshe RB, editor. Textbook of Human Virology, 2nd Edition, Mosby Year Book Inc. St. Louis; 1991:351-66.
4. Liang Y, Ma S, Yang Z, et al. Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine 2008;26(33):4276–83.
5. Somboonthum P, Yoshii H, Okamoto S, et al. Generation of a recombinant Oka varicella vaccine expressing mumps virüs hemagglutinin-neuraminidase protein as a polyvalent live vaccine.
Vaccine 2007;25(52):8741–55.
6. Jin L, Orvell C, Myers R, et al. Genomic diversity of mumps virüs and global distribution of the 12 genotypes. Rev Med Virol 2015;25(2):85–101.
7. Mumps virüs nomenclature update: 2012. Wkly Epidemiol Rec 2012 Jun 1;87(22):217-24.
8. Knowles WA, Jin L. Rubulavirüs: mumps virüs. In: Mahy BWJ, Meulen V, eds. Topley & Wilson’s microbiology & microbial infections, 10th Edition. Hodder Arnold, London, United Kingdom;
2005: 744-62.
9. Mühlemann K. The molecular epidemiology of mumps virüs. Infect Genet Evol. 2004 Sep 1;4(3):215–9.
10. Palacios G, Jabado O, Cisterna D, et al. Molecular Identification of Mumps Virüs Genotypes from Clinical Samples: Standardized Method of Analysis. J Clin Microbiol 2005;43(4):1869.
11. Gouma S, Cremer J, Parkkali S, Veldhuijzen I, van Binnendijk RS, Koopmans MPG. Mumps virüs F gene and HN gene sequencing as a molecular tool to study mumps virüs transmission.
Infect Genet Evol 2016;45:145–50.
12. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet 2008;371(9616):932–44.
13. Mumps Outbreak on a University Campus-California, 2011. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6148a2.htm
14. Morris PDJ. Mumps. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
15. Leland DS. Parainfluenza and Mumps Virüses. In: Jorgensen JH, Carroll KC, Funke G, Pfaller MA, Landry ML, Richter SS, Warnock DW, eds. Manual of Clinical Microbiology, Washington,
DC, USA: ASM Press, 2015:1487-97.
16. Maillet M, Bouvat E, Robert N, et al. Mumps outbreak and laboratory diagnosis. J Clin Virol 2015;62:14–9.
17. Cardemil CV, Dahl RM, James L, et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med 2017;377(10):947.
18. Updated Recommendations for Isolation of Persons with Mumps. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5740a3.htm.
19. Aşı Takvimi. https://asi.saglik.gov.tr/asi/asi-takvimi2.
KIZAMIK VİRÜSÜ
KAYNAKLAR
1. Berche P. History of measles. Presse Med 2022;51:104149.
2. Ting S, Nixon R. Clinical features of viral exanthems. Aust J Gen Pract 2021;50(4):231–6.
3. Guerra FM, Bolotin S, Lim G, et al. The basic reproduction number (R0) of measles: a systematic review. Lancet Infect Dis 2017;17(12):e420–8.
4. Kauffmann F, Heffernan C, Meurice F, Ota MOC, Vetter V, Casabona G. Measles, mumps, rubella prevention: how can we do better? Expert Rev Vaccines 2021;20(7):811–26.
5. Kondamudi NP WJ. Measles. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
6. Peart Akindele N. Updates in the Epidemiology, Approaches to Vaccine Coverage and Current Outbreaks of Measles. Infect Dis Clin North Am 2022;36(1):39–48.
7. Patel MK, Goodson JL, Alexander JP, et al. Progress Toward Regional Measles Elimination — Worldwide, 2000–2019. MMWR Morb Mortal Wkly Rep 2020;69(45):1700–5.
8. Countries in the European Region stepping up to stop the spread of measles as cases in 2023 already exceed all those in 2022. https://www.who.int/europe/news/item/26-04-2023-countries-
in-the-european-region-stepping-up-to-stop-the-spread-of-measles-as-cases-in-2023-already-exceed-all-those-in-2022
9. Nelson AN, Putnam N, Hauer D, Baxter VK, Adams RJ, Griffin DE. Evolution of T Cell Responses during Measles Virüs Infection and RNA Clearance. Sci Rep 2017;7(1).
10. Bentley J, Rouse J, Pinfield J. Measles: pathology, management and public health issues. Nurs Stand 2014;28(38):51–8.
11. Genetic Analysis of Measles Virüses. https://www.cdc.gov/measles/lab-tools/genetic-analysis.html#print
12. Griffin DE. Measles. In: Knipe DM, Howley PM, eds. Fields Virology, 6th edition. Wolter Kluwer/Lippincott Williams and Wilkins; 2013:1042–69.
13. Cockbain BC, Bharucha T, Irish D, Jacobs M. Measles in older children and adults. BMJ 2017;356.
14. Hübschen JM, Bork SM, Muller CP, et al. Challenges of measles and rubella laboratory diagnostic in the era of elimination. Clin Microbiol Infect 2017;23(8):511–5.
RESPİRATUVAR SİNSİTYAL VİRÜS
KAYNAKLAR
1. Morris JA, Blount RE, Savage RE. Recovery of Cytopathogenic Agent from Chimpanzees with Goryza. Proc Soc Exp Biol Med 1956;92(3):544–9.
2. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virüs related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg
1957;66(3):281–90.
3. Zhu C, Fu S, Zhou X, Yu L. Complete Genome Sequence of Human Respiratory Syncytial Virüs from Lanzhou, China. Genome Announc 2017;5(34):739–56.
4. McLellan JS, Ray WC, Peeples ME. Structure and Function of RSV Surface Glycoproteins. Curr Top Microbiol Immunol 2013;372:83.
5. Anderson LJ, Jadhao SJ, Paden CR, Tong S. Functional Features of the Respiratory Syncytial Virüs G Protein. Virüses 2021;13(7):1214.
6. Bayrakdar F, Kocabas CN, Altas AB, et al. Genetic variability human respiratory syncytial virüs subgroups A and B in Turkey during six successive epidemic seasons, 2009-2015. J Med Virol
2018;90(3):456–63.
7. Park GYS TK. Paramyxovirüs. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
8. Çağlar HT, Pekcan S, Yılmaz Aİ, et al. The epidemiologic trend of respiratory syncytial virüs has returned strongly to its origin after the pandemic: Five-year data from a single center. Pediatr
Pulmonol 2023;58(12):3582–7.
9. Shang Z, Tan S, Ma D. Respiratory syncytial virüs: from pathogenesis to potential therapeutic strategies. Int J Biol Sci 2021;17(14):4073.
10. Lotz MT, Moore ML, Peebles RS. Respiratory syncytial virüs and reactive airway disease. Curr Top Microbiol Immunol 2013;372:105–18.
11. Rozenbaum MH, Begier E, Kurosky SK, et al. Incidence of Respiratory Syncytial Virüs Infection in Older Adults: Limitations of Current Data. Infect Dis Ther 2023;12(6):1487–1504.
12. Perk Y, Özdil M. Respiratory syncytial virüs infections in neonates and infants. Turkish Arch Pediatr Pediatr Arşivi 2018;53(2):63.
13. Cody Meissner H. Respiratory Syncytial Virüs. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases, 4th edition, Elsevier Churchill Livingsto-
ne, Edinburgh; 2012:1185–1188.
14. Wilkins D, Wählby Hamrén U, Chang Y, et al. RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. Pediatrics. 2024 Nov 1;154(5):e2024067174. doi: 10.1542/
peds.2024-067174. PMID: 39350745.
15. https://www.merck.com/news/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-du-
ring-or-entering-their-fir/
16. U.S. Food and Drug Administration (FDA). (2023, August 21). FDA Approves First RSV Vaccine for Use During Pregnancy to Protect Infants.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-rsv-vaccine-use-during-pregnancy-protect-infants
17. Centers for Disease Control and Prevention (CDC). (2023, September 22). Use of RSVpreF Vaccine for Pregnant Women: Recommendations of the ACIP. MMWR, 72(38), 1063–1068.
https://www.cdc.gov/mmwr/volumes/72/wr/mm7238a4.htm
İNSAN METAPNÖMOVİRÜSÜ
KAYNAKLAR
1. Van Den Hoogen BG, De Jong JC, Groen J, et al. A newly discovered human pneumovirüs isolated from young children with respiratory tract disease. Nat Med 2001;7(6):719.
2. Baley JE, Gonzalez BE. Viral Infections in the Neonate. In: Fanaroff AA, Walsh MC, eds. Fanaroff and Martin’s Neonatal-Perinatal Medicine, 11th Edition. Elsevier; 2019: 844.
3. Banerjee S, Sullender WM, Choudekar A, et al. Detection and genetic diversity of human metapneumovirüs in hospitalized children with acute respiratory infections in India. J Med Virol
2011;83(10):1799.
4. Crowe JE. Human Metapneumovirüs. In: Kliegman RM, St. Geme III JW, eds. Nelson Textbook of Pediatrics, 21st Edition. Elsevier; 2020: 1738-1739.
5. Haas LEM, Thijsen SFT, van Elden L, Heemstra KA. Human Metapneumovirüs in Adults. Virüses 2013;5(1):87-110.
6. Jeong S, Park M-J, Song W, Kim H-S. Advances in laboratory assays for detecting human metapneumovirüs. Ann Transl Med 2020;8(9):608–608.
HENİPAVİRÜS
KAYNAKLAR
1. Sawatsky B, Ranadheera C, Weingarti HM, Czub M. Hendra and Nipah Virüs. In: Sobrino F, Mettenleiter TC, eds. Animal Virüses: Molecular Biology. Caister Academic Press; 2008.
2. Tulsiani SM, Graham GC, Moore PR, et al. Emerging tropical diseases in Australia. Part 5. Hendra virüs. Ann Trop Med Parasitol 2011;105(1):1–11.
3. Chua KB, Bellini WJ, Rota PA, et al. Nipah Virüs: A Recently Emergent Deadly Paramyxovirüs. Science 2000;288(5470):1432–5.
4. Rockx B, Winegar R, Freiberg AN. Recent progress in henipavirüs research: Molecular biology, genetic diversity, animal models. Antiviral Res 2012;95(2):135–49.
5. Thorner AR, Dolin R. Zoonotic Paramyxovirüses: Nipah, Hendra, and Menangle. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious
Diseases, 8th Edition. Elsevier Saunders Philadelphia; 2015:1974-1980.
6. Lo MK, Rota PA. The emergence of Nipah virüs, a highly pathogenic paramyxovirüs. J Clin Virol 2008;43(4):396–400.
7. Luby SP, Gurley ES. Epidemiology of Henipavirüs Disease in Humans. Current Topics in Microbiology and Immunology 2012;25–40.
8. Guillaume V, Lefeuvre A, Faure C, et al. Specific detection of Nipah virüs using real-time RT-PCR (TaqMan). J Virol Methods 2004;120(2):229–37.